SAN MATEO, Calif., July 11, 2025 /PRNewswire/ -- Today GoPro, Inc. (NASDAQ: GPRO) announced a United States Administrative Law Judge (ALJ) of the International Trade Commission (ITC) in Washington, D.C. issued an Initial Determination, finding that China-based Insta360 violated federal law by importing and selling in the United States products that infringe GoPro intellectual property covering GoPro's iconic HERO camera design.GoPro is pleased with the ALJ's findings that Insta360 infringed on a patent cove ...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Bubblr Inc., operating as Ethical Web AI (OTC: BBLR), a leader in secure, enterprise-grade generative AI, today announced a major achievement in executing its 2025 strategic roadmap. The company has successfully onboarded its first AI Vault SaaS client via the Amazon Web Services (AWS) Marketplace. AI Vault Lands First Client via AWS MarketplaceFollowing its recent debut on the AWS Marketplace, Ethical Web AI’s flagship product, AI Vault, has secured its first ent ...

Core Insights - Hoth Therapeutics has secured Japan Country Patent No. 7677628 for its HT-KIT platform, providing exclusive protection until August 27, 2039 [1][6] - The patent covers a novel method using splice-switching oligonucleotides (SSOs) to target KIT gene expression in mast cells, which are involved in various conditions including chronic hives and rare cancers [2][6] - The CEO of Hoth Therapeutics emphasized the strategic importance of this patent in the Asian pharmaceutical market and the potential for licensing opportunities [3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at improving patient quality of life [4] - The company is actively seeking global partners for co-development and commercialization of its therapeutic platforms, particularly in Asia [3] Patent Details - The granted patent is specifically applicable to mast cell-driven inflammatory and oncologic conditions, positioning the company for orphan indications and expedited regulatory pathways [6]

Core Viewpoint - Treace Medical Concepts, Inc. has filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. for patent infringement related to its Lapiplasty® 3D Bunion Correction® technologies, seeking injunctive relief and damages [1]. Group 1: Company Overview - Treace Medical Concepts is a medical technology company focused on advancing surgical treatment for bunions and midfoot deformities, with an estimated 67 million Americans affected by bunions, of which 1.1 million are annual surgical candidates [3]. - The company has developed and patented the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in three planes and stabilizing the affected joint [3]. - Treace's patent portfolio includes 80 granted U.S. patents and 26 granted patents worldwide, along with over 150 pending patent applications, highlighting its commitment to innovation and intellectual property protection [2]. Group 2: Legal Action - The lawsuit filed by Treace aims to protect its significant investments in research and technology, emphasizing the importance of enforcing intellectual property rights to foster continued innovation [2]. - The legal action is seen as a necessary step to safeguard the company's pioneering position in the surgical treatment of bunions [2].

ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently ...

Core Viewpoint - Scienture Holdings, Inc. has announced the FDA listing of two patents for its product Arbli, a novel oral liquid formulation of losartan, which is expected to enhance its market position and provide statutory exclusivity under the Hatch-Waxman Act [1][2][6]. Company Overview - Scienture Holdings, Inc. is a holding company focused on developing and distributing specialty pharmaceutical products that address unmet market needs [1][13]. - The company operates through its subsidiary, Scienture, LLC, which is dedicated to bringing unique specialty products to market [13]. Product Details - Arbli is the first FDA-approved ready-to-use oral liquid formulation of losartan, designed for patients over 6 years old, and is indicated for the treatment of hypertension and related conditions [3][4][8]. - The product is available in a 165 mL bottle with a peppermint flavor, has a shelf life of 18 months at room temperature, and does not require refrigeration [7]. Market Position - The patents for Arbli cover stable liquid formulations of losartan and methods of use, reinforcing Scienture's intellectual property position [2]. - Losartan is classified as an angiotensin receptor blocker (ARB) and is one of the most prescribed medications for hypertension, with annual sales of approximately $276 million and a prescription volume of 69 million in the U.S. market as of March 2025 [5]. Regulatory Milestone - The listing of Arbli in the FDA's Orange Book is considered a significant regulatory achievement for Scienture, validating its development efforts and enhancing its commercial pathway in the U.S. market [6][2].

BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced the filing of a copyright infringement and breach of contract lawsuit against Microsoft and Nuance Communications in the United States District Court for the District of Delaware. Cerence AI and its predecessors have an extensive history of industry-leading innovation and technological achievement. This has resulted in a strong ...